| ACOG | American College of Obstetricians and Gynecologists |
| ACR | American College of Rheumatology |
| AIA | Aromatase inhibitors-associated arthralgia |
| AIs | Aromatase inhibitors |
| Anti-CCP | anti-cyclic citrullinated protein antibodies |
| aPL | anti-phospholipid antibodies |
| APS | Antiphospholipid syndrome |
| ArKO | Aromatase gene knockout |
| ASAS | Anti-synthetase antibody syndrome |
| ASCO | American Society of Clinical Oncology |
| BC | Breast cancer |
| Bcl-2 protein | B cell lymphoma-2 protein |
| BMD | Bone mineral density |
| BMI | Body mass index |
| BPI-SF | Brief pain inventory—short form |
| CDK | Cycline dependent kynase |
| CRP | C reactive protein |
| CTLs | Cytotoxic-T-lymphocytes |
| CV | Cardiovascular |
| DAS | Disease activity score |
| DASH | Disabilities of the arm, shoulder and hand |
| DLE | Discoid lupus erythematosus |
| DXA | Dual-energy X-ray absorptiometry |
| E1 | Estrone |
| E2 | Estradiol |
| ELPh | Exemestane and letrozole pharmacogenetics |
| ER | Estrogen receptors |
| ESMO | European Society of Medical Oncology |
| ESR | Erythrocyte sedimentation rate |
| FACT-ES TOI | Functional Assessment of Cancer Therapy-Endocrine Scale Trial Outcome Index |
| FDA | Food and Drug Administration |
| GSM | Genitourinary syndrome of menopause |
| GWAS | Genome-Wide Association Study |
| HAQII | Health Assessment Questionnaire II |
| HLA | Human leucocyte antigen |
| HR | Hazard ratio |
| IGF | Insulin-like growth factor |
| IL | Interleukin |
| IL-17RA | Interleukin-17 receptor A |
| INF | Interferon |
| IR | Incident rate |
| IRF | Interferon regulatory factor |
| LHRH | Luteinizing hormone-releasing hormone |
| MCF | Metacarpo-phalangeal |
| MCP | Monocyte chemoattractant protein |
| MHC | Major histocompatibility complex |
| MMP-3 | Metalloproteinases-3 |
| MRI | Magnetic resonance imaging |
| M-SACRAH | Modified score for the assessment and quantification of chronic rheumatoid affection of the hands |
| NO | Nitric oxide |
| NSAIDs | Non-steroidal anti-inflammatory drugs |
| O3-FAs | Omega-3 fatty acids |
| OA | Osteoarthritis |
| OMERACT-OARSI | Outcome Measures in Rheumatology Clinical Trials and Osteoarthritis Research Society International |
| OPG | Osteoprotegerin |
| PD-1 | Programmed cell death receptor |
| PDL1 | PD-1 ligand-1 |
| PG | Prostaglandin |
| PIP | Proximal inter-phalangeal |
| PR | Progesterone receptors |
| RA | Rheumatoid arthritis |
| RANKL | Receptor activator of nuclear factor-kB ligand |
| RCTs | Randomized controlled trials |
| RF | Rheumatoid factor |
| SERD | Selective estrogen receptor down-regulators |
| SERM | Selective estrogen receptor modulator |
| SjS | Sjogren syndrome |
| SLE | Systemic lupus erythematosus |
| SNPs | Single-nucleotide polymorphisms |
| SpA | Spondyloarthropaty |
| SS | Systemic sclerosis |
| SSA | Sjogren syndrome-associated autoantigen |
| TCL1A | T-cell leukemia 1A |
| TNF | Tumor necrosis factor |
| US | Ultrasound |
| VDBP | Vitamin D-binding protein |
| VDR | Vitamin D receptor |
| WOMAC | Western Ontario and McMaster Universities Osteoarthritis index |